Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli, Diego Signorelli, Michele Ghidini et al. · Cancers · 2020
Immune checkpoint inhibitors (ICIs) can elicit toxicities by inhibiting negative regulators of adaptive immunity. Sometimes, management of toxicities may require systemic glucocorticoids. We performed a systematic review and meta-analysis of published studies to evaluate the correlation between steroids use, overall survival (OS), and progression-free survival (PFS) in cancer patients treated with ICIs. Publications that compared steroids with non-steroid users in cancer patients treated with ICIs from inception to June 2019 were identified by searching the EMBASE, PubMed, SCOPUS, Web of Science, and Cochrane Library databases. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Patients (studies, n = 16; patients, n = 4045) taking steroids were at increased risk of death and progression compared to those not taking steroids (HR = 1.54, 95% CI: 1.24–1.91; p = 0.01 and HR = 1.34, 95% CI: 1.02–1.76; p = 0.03, respectively). The main negative effect on OS was associated with patients taking steroids for supportive care (HR = 2.5, 95% CI 1.41–4.43; p < 0.01) or brain metastases (HR = 1.51, 95% CI 1.22–1.87; p < 0.01). In contrast, steroids used to mitigate adverse events did not negatively affect OS. In conclusion, caution is needed when steroids are used for symptom control. In these patients, a negative impact of steroid use was observed for both OS and PFS.
Cited by 299 works. doi:10.3390/cancers12030546 Open-access PDF
Authors
- Fausto Petrelli
- Diego Signorelli
- Michele Ghidini
- Antonio Ghidini
- Elio Gregory Pizzutilo
- Lorenzo Ruggieri
- Mary Cabiddu
- Karen Borgonovo
- Giuseppina Patrizia Dognini
- Matteo Brighenti
- Alessandro De Toma
- Erika Rijavec
- Marina Chiara Garassino
- Francesco Grossi
- Gianluca Tomasello
References
- Meta-analysis of Observational Studies in Epidemiology A Proposal for Reporting
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
- The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- Macrophage plasticity and polarization: in vivo veritas
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC